SCHEMBL23668182

SCHEMBL23668182

Cc1ccc(S(=O)(=O)n2cc(-c3nc(Cl)ncc3C)c3ccnc(Cl)c32)cc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ABL1 P00519 1/20 0.39
▸ BCR P11274 1/20 0.39
▸ BRD4 O60885 5/20 0.38
▸ L3MBTL1 Q9Y468 3/20 0.37
▸ PDE4A P27815 1/20 0.36
▸ PDE4B Q07343 1/20 0.36
▸ PDE4C Q08493 1/20 0.36
▸ PDE4D Q08499 1/20 0.36
▸ HTR6 P50406 3/20 0.35
▸ ALDH1A1 P00352 2/20 0.34
▸ KDM4E B2RXH2 2/20 0.34
▸ UBE2N P61088 1/20 0.34
▸ HPGD P15428 1/20 0.34
▸ HTT P42858 2/20 0.33
▸ POLB P06746 1/20 0.33
▸ ALDH3A1 P30838 1/20 0.33
▸ NOD1 Q9Y239 1/20 0.33
▸ GRM4 Q14833 1/20 0.33
▸ NPSR1 Q6W5P4 1/20 0.33
▸ HSD11B1 P28845 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30810135 0.84 BRD4 (0.44) ABL1BCRBRD4L3MBTL1PDE4A
SCHEMBL23668186 0.84 BRD4 (0.44) ABL1BCRBRD4L3MBTL1PDE4A
SCHEMBL18662695 0.81 PIN1 (0.39) ABL1BCRBRD4L3MBTL1HTR6
SCHEMBL29394664 0.81 PIN1 (0.39) ABL1BCRBRD4L3MBTL1HTR6
SCHEMBL23668192 0.80 JAK1 (0.47) —
SCHEMBL23668176 0.76 L3MBTL1 (0.42) BRD4L3MBTL1HTR6ALDH1A1KDM4E
SCHEMBL30810137 0.76 L3MBTL1 (0.42) BRD4L3MBTL1HTR6ALDH1A1KDM4E
SCHEMBL6039554 0.74 HTR6 (0.58) L3MBTL1HTR6DRD2HTR2AHTR7
SCHEMBL18662641 0.73 HSD11B1 (0.40) ABL1BCRBRD4L3MBTL1HTR6
SCHEMBL29394672 0.73 HSD11B1 (0.40) ABL1BCRBRD4L3MBTL1HTR6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12234232-B2 Aromatic heterocyclic compound with kinase inhibitory activity SHANGHAI ENNOVABIO PHARMACEUTICALS CO., LTD. (CN) 2025-02-25 — — US disclosed
US-20210371415-A1 AROMATIC HETEROCYCLIC COMPOUND WITH KINASE INHIBITORY ACTIVITY SHANGHAI ENNOVABIO PHARMACEUTICALS CO., LTD. (CN) 2021-12-02 — — US disclosed
EP-3854793-A1 AROMATIC HETEROCYCLIC COMPOUND WITH KINASE INHIBITORY ACTIVITY Shanghai Ennovabio Pharmaceuticals Co., Ltd. (CN) 2021-07-28 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210371415-A1 AROMATIC HETEROCYCLIC COMPOUND WITH KINASE INHIBITORY ACTIVITY JAK1, JAK2, JAK3 ABL1 11/4885BCR 320/4885BRD4 541/4885
US-12234232-B2 Aromatic heterocyclic compound with kinase inhibitory activity JAK1, JAK2, JAK3 ABL1 11/4885BCR 320/4885BRD4 541/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback